Pariet

Pariet

rabeprazole

Manufacturer:

Eisai

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Rabeprazole Na
Indications/Uses
Prevention of gastric & duodenal ulcer recurrences associated w/ low-dose aspirin therapy. Active duodenal & benign gastric ulcer; symptomatic erosive or ulcerative GERD. GERD long-term management. Symptomatic treatment of moderate to very severe GERD. H. pylori eradication in patients w/ PUD in combination w/ appropriate antibacterial therapeutic regimens.
Dosage/Direction for Use
Prevention of gastric & duodenal ulcer recurrences associated w/ low-dose aspirin therapy Adult/elderly Usual dose: 5 mg once daily, may be increased to 10 mg once daily. Active duodenal & benign gastric ulcer, & erosive or ulcerative GERD Usual dose: 10 mg once daily, may be increased up to 20 mg once daily depending on severity of symptoms. Duration of treatment: Up to 8 wk for active benign gastric ulcer & symptomatic erosive or ulcerative GERD; 6 wk for active duodenal ulcer. Reflux esophagitis patient who do not respond to usual doses of proton pump inhibitor treatment 10 mg bd for a further 8 wk. Patient w/ severe mucosa injury 20 mg bd. GERD long-term management maintenance 10 or 20 mg once daily. Maintenance therapy of reflux esophagitis when proton pump inhibitor treatment is ineffective May administer 10 mg bd. Symptomatic treatment of moderate to very severe GERD 10 mg once daily in patients w/o esophagitis. Further investigate if symptom control is not achieved in 4 wk. Once symptoms are resolved, achieve subsequent symptom control using on-demand regimen w/ 10 mg once daily. H. pylori eradication Pariet 20 mg bd + clarithromycin 500 mg bd & amoxicillin 1 g bd. Duration of treatment: 7 days.
Administration
May be taken with or without food: Swallow whole, do not chew/crush.
Contraindications
Hypersensitivity to rabeprazole Na & substituted benzimidazoles. Pregnancy & lactation.
Special Precautions
Exclude malignancy prior to commencing treatment. Monitor patients on long-term treatment particularly those treated for >1 yr. Risk of osteoporosis-related fractures eg, hip, wrist, or spine. Monitor for hypomagnesemia. Concomitant use w/ digoxin or hypomagnesemia-causing drugs (diuretics); methotrexate. Consider diagnosis of Clostridium difficile-associated diarrhea in patients w/ non-improving diarrhea. Severe hepatic dysfunction. May affect ability to drive or operate machinery. Not recommended in childn.
Adverse Reactions
Increased BP; stomatitis. Infection; palpitations; insomnia; headache, dizziness; cough, pharyngitis, rhinitis; diarrhoea, vomiting, nausea, abdominal pain, constipation, flatulence, benign fundic gland polyps; non-specific pain, back pain; asthenia, flu-like illness.
Drug Interactions
Decreased ketoconazole serum levels. Increased trough digoxin serum levels. May reduce atazanavir exposure. Decreased rilpivirine HCl blood conc. May elevate & prolong serum levels of methotrexate &/or its metabolite hydroxymethotrexate.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BC04 - rabeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Presentation/Packing
Form
Pariet tab 10 mg
Packing/Price
14's
Form
Pariet tab 20 mg
Packing/Price
14's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in